Characterization of an In Vivo Neutralizing Anti-Vaccinia Virus D8 Single-Chain Fragment Variable (scFv) from a Human Anti-Vaccinia Virus-Specific Recombinant Library

A panel of potent neutralizing antibodies are protective against orthopoxvirus (OPXV) infections. For the development of OPXV-specific recombinant human single-chain antibodies (scFvs), the IgG repertoire of four vaccinated donors was amplified from peripheral B-lymphocytes. The resulting library consisted of ≥4 × 108 independent colonies. The immuno-screening against vaccinia virus (VACV) Elstree revealed a predominant selection of scFv clones specifically binding to the D8 protein. The scFv-1.2.2.H9 was engineered into larger human scFv-Fc-1.2.2.H9 and IgG1-1.2.2.H9 formats to improve the binding affinity and to add effector functions within the human immune response. Similar binding kinetics were calculated for scFv-1.2.2.H9 and scFv-Fc-1.2.2.H9 (1.61 nM and 7.685 nM, respectively), whereas, for IgG1-1.2.2.H9, the Michaelis-Menten kinetics revealed an increased affinity of 43.8 pM. None of the purified recombinant 1.2.2.H9 formats were able to neutralize VACV Elstree in vitro. After addition of 1% human complement, the neutralization of ≥50% of VACV Elstree was achieved with 0.0776 µM scFv-Fc-1.2.2.H9 and 0.01324 µM IgG1-1.2.2.H9, respectively. In an in vivo passive immunization NMRI mouse model, 100 µg purified scFv-1.2.2.H9 and the IgG1-1.2.2.H9 partially protected against the challenge with 4 LD50 VACV Munich 1, as 3/6 mice survived. In contrast, in the scFv-Fc-1.2.2.H9 group, only one mouse survived the challenge.

Parasite-host dynamics throughout antimalarial drug development stages complicate the translation of parasite clearance

Ensuring continued success against malaria depends on a pipeline of new antimalarials. Antimalarial drug development utilizes pre-clinical murine and experimental human malaria infection studies to evaluate drug efficacy. A sequential approach is typically adapted, with results from each stage, informing the design of the next stage of development. The validity of this approach depends on confidence that results from murine malarial studies predict the outcome of clinical trials in humans. Parasite clearance rates following treatment are key parameters of drug efficacy. To investigate the validity of forward predictions, we developed a suite of mathematical models to capture parasite growth and drug clearance along the drug development pathway and estimated parasite clearance rates. When comparing the three infection experiments, we identified different relationships of parasite clearance with dose, and different maximum parasite clearance rates: in P. berghei-NMRI mouse infections we estimated a maximum parasite clearance rate of 0.2 [1/h]; in P. falciparum-SCID mouse infections 0.05 [1/h]; while in human volunteer infection studies with P. falciparum, we found a maximum parasite clearance rate of 0.12 [1/h] and 0.18 [1/h] after treatment with OZ439 and MMV048, respectively. Sensitivity analysis revealed that host-parasite driven processes account for up to 25% of variance in parasite clearance for medium-high doses of antimalarials. Although there are limitations in translating parasite clearance rates across these experiments, they provide insight into characterising key parameters of drug action and dose response, and assist in decision-making regarding dosage for further drug development.

Assessment of Mitochondrial Function and Developmental Potential of Mouse Oocytes after Mitoquinone Supplementation during Vitrification

Vitrification negatively affects the mitochondrial membrane potential (ΔΨm) in oocytes while also leading to increased reactive oxygen species (ROS), ATP depletion and induction of apoptosis in oocytes. Mitoquinone (MitoQ) is an antioxidant that protects mitochondrial membrane integrity from ROS. This study examined the effect of adding MitoQ to vitrification medium on mitochondrial function and embryo development in vitrified oocytes. Metaphase II (MII) stage oocytes were collected from NMRI mouse ovaries and preincubated for 20 min in a medium containing 0.02 µM of MitoQ. Next, oocytes were vitrified in medium supplemented with 0.02 μM of MitoQ (treatment group). The control group was processed in the same way but without exposure to MitoQ. After warming, oocyte survival rate, ΔΨm, cytoplasmic ROS and glutathione (GSH) levels and gene expression levels (Bcl2, BAX, and caspase3) were measured. In addition, the vitrified oocytes were fertilized in-vitro to assess developmental competence. The results showed that MitoQ improved survival and ΔΨm in treated vitrified oocytes. Treated oocytes showed lower ROS levels and higher GSH levels than did the control group. Furthermore, mRNA expression of the Bax/Bcl2 ratio and caspase3 were significantly lower in treated oocytes. These findings indicate that medium supplementation with 0.02 μM of MitoQ during vitrification can improve oocyte survival and developmental competency in mouse oocytes.

High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in Pex1-G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment

Genetic alterations in PEX genes lead to peroxisome biogenesis disorder. In humans, they are associated with Zellweger spectrum disorders (ZSD). No validated treatment has been shown to modify the dismal natural history of ZSD. Liver transplantation (LT) improved clinical and biochemical outcomes in mild ZSD patients. Hepatocyte transplantation (HT), developed to overcome LT limitations, was performed in a mild ZSD 4-year-old child with encouraging short-term results. Here, we evaluated low dose (12.5 million hepatocytes/kg) and high dose (50 million hepatocytes/kg) syngeneic male HT via intrasplenic infusion in the Pex1-G844D NMRI mouse model which recapitulates a mild ZSD phenotype. HT was feasible and safe in growth retarded ZSD mice. Clinical (weight and food intake) and biochemical parameters (very long-chain fatty acids, abnormal bile acids, etc.) were in accordance with ZSD phenotype but they were not robustly modified by HT. As expected, one third of the infused cells were detected in the liver 24 h post-HT. No liver nor spleen microchimerism was detected after 7, 14 and 30 days. Future optimizations are required to improve hepatocyte engraftment in Pex1-G844D NMRI mouse liver. The mouse model exhibited the robustness required for ZSD liver-targeted therapies evaluation.

Fresh and cultured mouse islets differ in their response to nutrient stimulation

Observing different kinetics of nutrient-induced insulin secretion in fresh and cultured islets under the same condition we compared parameters of stimulus secretion coupling in freshly isolated and 22-h-cultured NMRI mouse islets. Stimulation of fresh islets with 30 mM glucose after perifusion without nutrient gave a continuously ascending secretion rate. In 22-h-cultured islets the same protocol produced a brisk first phase followed by a moderately elevated plateau, a pattern regarded to be typical for mouse islets. This was also the response of cultured islets to the nutrient secretagogue alpha-ketoisocaproic acid, whereas the secretion of fresh islets increased similarly fast but remained strongly elevated. The responses of fresh and cultured islets to purely depolarizing stimuli (tolbutamide or KCl), however, were closely similar. Signs of apoptosis and necrosis were rare in both preparations. In cultured islets, the glucose-induced rise of the cytosolic Ca2+ concentration started from a lower value and was larger as was the increase of the ATP/ADP ratio. The prestimulatory level of mitochondrial reducing equivalents, expressed as the NAD(P)H/FAD fluorescence ratio, was lower in cultured islets, but increased more strongly than in fresh islets. When culture conditions were modified by replacing RPMI with Krebs–Ringer medium and FCS with BSA, the amount of released insulin varied widely, but the kinetics always showed a predominant first phase. In conclusion, the secretion kinetics of fresh mouse islets is more responsive to variations of nutrient stimulation than cultured islets. The more uniform kinetics of the latter may be caused by a different use of endogenous metabolites.

Evaluating the Effects of Different Concentrations of Human Follicular Fluid on Growth, Development, and PCNA Gene Expression of Mouse Ovarian Follicles

Follicle culture in vitro provides a method for investigating stages of folliculogenesis that can lead to preserving fertility through cryopreservation techniques. This study aims to assess the effects of various concentrations of human follicular fluid (hFF) on growth, development, and expression of the proliferating cell nuclear antigen (PCNA) gene in mouse ovarian follicles in vitro. Preantral follicles were isolated from 14-day NMRI mouse ovaries. The follicles were cultured in basic media enriched with FBS, FSH, and insulin-transferrin-selenium, and supplemented with different concentrations of hFF (10, 20, and 30%) for 12 days. During the culture period, survival rate and follicular maturation, follicular diameter, levels of estrogen and progesterone secretion, and PCNA gene expression rate were evaluated. Survival rate, maturation, and antrum formation were significantly higher in the 10% hFF group than in the 20 and 30% hFF groups. On day 4, follicle diameter in the 10% hFF group was also higher than in the 20 and the 30% hFF group. In comparison with other groups, significantly higher estrogen and progesterone production levels were measured in the 10% hFF group. PCNA gene expression was also higher with 10 than 20 and 30% hFF concentrations. The present study suggests that addition of 10% hFF to mice ovarian preantral follicle culture media enhances follicle growth and oocyte maturation.

Antioxidant and Anti-Inflammatory Activities of Caralluma Acutangula (Decne.) N.E.Br Extracts, a Medicinal Plant from Burkina Faso

Plants have always played an important role in health care in Africa. The stress, a situation of imbalance between oxidizing and antioxidant systems in favor of the prooxidants is responsible for the installation of several pathologies such as cancers, cardiovascular diseases, diabetes ... The objective of this study was to highlight the presence Secondary metabolites in C. acutangula extract and determine its antioxidant and anti-inflammatory potential. For the determination of the acute toxicity of the extract, a dose of 2000 mg / kg was administered to the NMRI Mouse. The methods of screening were used to detect secondary metabolites like tannins, steroids and terpen, flavonoids, coumarins. The antioxidant capacity was evaluated in vitro by determining the ability of the extract to inhibit lipid peroxidation, hydrogen peroxide, degradation of deoxyribose. The anti-inflammatory potential was evaluated on lipoxygenase and xanthine oxidase. Acute toxicity evaluated in NMRI mice showed that the ethanolic extract of C. acutangula show no toxicity. Tannins, steroids and terpen, flavonoids, coumarins have been detected in the extracts. C. acutangula showed good activity with an inhibition of 50.71 ± 2.51% at 100 μg / ml on lipid peroxidation, of 66.105 ± 1.26% on deoxyribose degradation and 8.625 ± 1.09% on hydrogen peroxide. It showed good activity on xanthine oxidase with an 81.5 ± 5.5% inhibition. For the effect on lipoxygenase it gave an inhibition of the enzyme at 43.11 ± 3.4%. This potential could be used in the fight against inflammatory diseases and that due to oxidative stress. Keywords: antioxidant, anti-inflammatory, oxidative stress, lipid peroxidation